J. Willemse

发表

A role for procarboxypepidase U (TAFI) in thrombosis.

J. Willemse, D. Hendriks, 2007, Frontiers in bioscience : a journal and virtual library.

Carboxypeptidase U (TAFIa) activity is induced in vivo in ischemic stroke patients receiving thrombolytic therapy

P. D. De Deyn, R. Brouns, P. De Deyn, 2007, Journal of thrombosis and haemostasis : JTH.

Carboxypeptidase U (TAFIa): a new drug target for fibrinolytic therapy?

M. Nesheim, J. Willemse, D. Hendriks, 2009, Journal of thrombosis and haemostasis : JTH.

Procarboxypeptidase U (TAFI) contributes to the risk of thrombosis in patients with hereditary thrombophilia.

D. Radojkovic, P. Miljić, I. Elezović, 2009, Thrombosis research.

The role of the S1 binding site of carboxypeptidase M in substrate specificity and turn-over.

A. Lambeir, K. Gilany, G. Surpateanu, 2007, Biochimica et biophysica acta.

Development of a fast kinetic method for the determination of carboxypeptidase U (TAFIa) using C-terminal arginine containing peptides as substrate.

R. Verkerk, J. Willemse, D. Hendriks, 2005, Analytical biochemistry.

The decrease in procarboxypeptidase U (TAFI) concentration in acute ischemic stroke correlates with stroke severity, evolution and outcome

P. D. De Deyn, R. Brouns, R. Sheorajpanday, 2010, Journal of thrombosis and haemostasis : JTH.

Measurement of procarboxypeptidase U (TAFI) in human plasma: a laboratory challenge.

J. Willemse, D. Hendriks, 2006, Clinical chemistry.

Influence of separator gel in Sarstedt S-Monovette® serum tubes on various therapeutic drugs, hormones, and proteins.

H. Neels, N. Van Regenmortel, A. Wauters, 2012, Clinica chimica acta; international journal of clinical chemistry.

LETTERS TO THE EDITOR: Fast kinetic assay for the determination of procarboxypeptidase U (TAFI) in human plasma

J. Willemse, D. Hendriks, J. Leurs, 2005, Journal of thrombosis and haemostasis : JTH.

Procarboxypeptidase U (TAFI) and the Thr325Ile proCPU polymorphism in patients with hereditary mucocutaneous hemorrhages.

O. Panes, V. Matus, T. Quiroga, 2009, Clinica chimica acta; international journal of clinical chemistry.

An update on the role of carboxypeptidase U (TAFIa) in fibrinolysis.

J. Willemse, D. Hendriks, E. Heylen, 2011, Frontiers in bioscience.

Chloral hydrate intoxication in a 3-month-old child: avoidance of hemodialysis by an immediate determination of trichloroethanol.

H. Neels, P. Van hee, J. Willemse, 2010, Clinical biochemistry.

Limited mutagenesis increases the stability of human carboxypeptidase U (TAFIa) and demonstrates the importance of CPU stability over proCPU concentration in down‐regulating fibrinolysis

P. Cronet, H. Stenhamre, Anna Harrysson, 2006, The FEBS journal.

Ethanol dependence of α1‐antitrypsin C‐terminal Lys truncation mediated by basic carboxypeptidases

H. Ehrlich, H. Schwarz, H. P. Matthiessen, 2008, Transfusion.

Carboxypeptidase U (TAFIa) decreases the efficacy of thrombolytic therapy in ischemic stroke patients

P. Deyn, R. Brouns, R. Sheorajpanday, 2009, Clinical Neurology and Neurosurgery.

The intrinsic enzymatic activity of procarboxypeptidase U (TAFI) does not significantly influence the fibrinolysis rate: a rebuttal

J. Willemse, D. Hendriks, E. Heylen, 2007, Journal of thrombosis and haemostasis : JTH.

The intrinsic enzymatic activity of plasma procarboxypeptidase U (TAFI) can interfere with plasma carboxypeptidase N assays.

J. Willemse, D. Hendriks, M. Polla, 2006, Analytical biochemistry.

Influence of the Thr325Ile polymorphism on procarboxypeptidase U (thrombin‐activable fibrinolysis inhibitor) activity‐based assays

V. Matus, D. Mezzano, J. Willemse, 2007, Journal of thrombosis and haemostasis : JTH.

Measurement of Procarboxypeptidase U in Human Plasma : A Laboratory Challenge

J. Willemse, D. Hendriks, 2005 .

Prochlorperazine in childhood: Side-effects

J. Willemse, A. V. Heyst, S. A. Pikaar, 1978, Clinical Neurology and Neurosurgery.

Development of a sensitive and selective assay for the determination of procarboxypeptidase U (thrombin-activatable fibrinolysis inhibitor) in plasma.

K. Augustyns, T. Olsson, S. Van Goethem, 2010, Analytical biochemistry.

Thrombin activatable fibrinolysis inhibitor (TAFI): a molecular link between coagulation and fibrinolysis.

D. Radojkovic, P. Miljić, I. Elezović, 2010, Srpski arhiv za celokupno lekarstvo.

Thrombin a ctivatable Fibrinolysis inhibitor (T a F i ): a Molecular l ink Between Coagulation and Fibrinolysis

J. Willemse, D. Hendriks, M. Čolović, 2010 .

Comparative substrate specificity study of carboxypeptidase U (TAFIa) and carboxypeptidase N: development of highly selective CPU substrates as useful tools for assay development.

T. Olsson, J. Willemse, D. Hendriks, 2008, Clinica chimica acta; international journal of clinical chemistry.

A rapid and sensitive assay for the quantitation of carboxypeptidase N, an important regulator of inflammation.

J. Willemse, D. Hendriks, 2006, Clinica chimica acta; international journal of clinical chemistry.

Comparative study of commercially available procarboxypeptidase U (thrombin‐activatable fibrinolysis inhibitor) assays

J. Willemse, D. Hendriks, E. Heylen, 2011, Journal of thrombosis and haemostasis : JTH.

Major carboxypeptidase N deficiency.

J. Willemse, D. Hendriks, David Chen, 2008, Clinica chimica acta; international journal of clinical chemistry.

Carboxypeptidase U (TAFIa): a new drug target for fibrinolytic therapy?

M. Nesheim, J. Willemse, D. Hendriks, 2009, Journal of thrombosis and haemostasis : JTH.

The decrease in procarboxypeptidase U (TAFI) concentration in acute ischemic stroke correlates with stroke severity, evolution and outcome

R. Sheorajpanday, R. Verkerk, J. Willemse, 2010, Journal of thrombosis and haemostasis : JTH.